Mardozia

Dorzolamide/Timolol, the active ingredient in Mardozia, is a carbonic anhydrase inhibitor / beta blocker presented as eye drops for ocular use. It lowers intra‑ocular pressure in adult patients with primary open‑angle glaucoma or ocular hypertension.

GNH USA supplies Mardozia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable logistics for bulk and individual orders. The product is manufactured under GMP conditions and holds a valid EU marketing authorization.

Mardozia is used in the management of ocular conditions that involve elevated intra‑ocular pressure.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage and preserve visual field. - Ocular hypertension: lowers eye pressure to prevent progression to glaucoma. - Post‑surgical ocular pressure control: helps maintain target pressure after ocular procedures.

The most frequently reported ocular and systemic reactions to Mardozia are listed below.

Common Side Effects: - Eye irritation or burning sensation - Temporary blurred vision - Bitter taste after instillation - Eye redness - Headache

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angioedema, anaphylaxis) - Significant bradycardia or heart block - Bronchospasm in susceptible individuals - Persistent corneal ulceration

Before prescribing Mardozia, clinicians should consider the following precautions.

- Assess baseline intra‑ocular pressure: ensure appropriate target pressure is set. - Monitor for systemic beta‑blocker effects: watch for bradycardia, hypotension, or bronchospasm. - Evaluate sulfonamide allergy: dorzolamide contains a sulfonamide moiety. - Use with caution in patients with severe asthma or chronic obstructive pulmonary disease. - Store at room temperature: keep in the original container, protect from light and moisture.

Mardozia may interact with other medications; notable interactions are categorized below.

Major Interactions (Avoid): - Concomitant non‑selective beta‑blockers: risk of additive bradycardia and hypotension. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): may cause excessive reduction of aqueous humor production. - Sympathomimetic eye drops (e.g., epinephrine): can diminish the IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Other ocular hypotensive agents (e.g., prostaglandin analogues): may require dose adjustment. - Antihypertensive drugs (e.g., calcium channel blockers): monitor blood pressure and heart rate. - Antidepressants affecting serotonergic pathways: observe for rare cardiac effects.